The U.S. health regulator has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active pharmaceutical ingredients (APIs) plant. The U.S. Food and Drug Administration (USFDA) identified deviations from Current Good Manufacturing Practice for APIs during inspections on multiple dates in 2024. The company must address the deficiencies within 15 working days to prevent further regulatory action and ensure compliance with CGMP requirements.
Full Article
French nuclear-powered carrier makes first visit to Philippines
France's ambassador to the Philippines emphasized the importance of freedom of navigation exercises in the South China Sea amid rising tensions, as the nuclear-powered Charles De Gaulle made its first port visit to the country. The aircraft carrier strike group conducted drills with the Philippine Navy to enhance interoperability and defense capabilities in the disputed waterway, signaling support for countries upholding international law and freedom of navigation. The visit comes as the Philippines seeks to...
Read more